Home > Research > Scientific Programmes: Clinical Research Programme > H12O-CNIO Lung Cancer Clinical Research Unit

Clinical Research Programme

H12O-CNIO Lung Cancer Clinical Research Unit

Head of Unit:  Luis Gonzaga Paz-Ares
Overview

Our Group combines basic preclinical studies with clinical and translational research, mainly in lung cancer and other solid tumours. In summary, the main research areas of our Group focus on 2 modalities: (1) the identification of new molecular biomarkers that can be used in the clinic for diagnostic, prognostic, predictive and pharmacogenomic purposes; and (2) developing novel treatment strategies. For example, we have comprehensively profiled bronchoalveloar lavage (BLA) fluids of COPD and lung cancer patients, showing a differential mi-RNA, protein and inflammatory cytokine expression between both diseases and different subtypes of lung cancer. On the other hand, we have developed a patient-derived xenograft (PDX) platform of non-small-cell lung cancers to test new drugs/targets. We are also developing PDXs of small-cell lung cancers. Finally, our Group has extensive experience in the development of new drugs, as well as in conducting practice-changing phase II/III trials in the fields of precision oncology and immunooncology.